Safety and immunogenicity of a quadrivalent intradermal influenza vaccine in adults

Gorse, Geoffrey J.; Falsey, Ann R.; Ozol-Godfrey, Ayca; Landolfi, Victoria; Tsang, Peter

doi:10.1016/j.vaccine.2015.01.025

Cited by 33 publications

(25 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As a result, this platform can be much more nimble than classical approaches based on egg-or tissue culture-adapted viruses. Herein we report the results of a phase 1-2 dose-escalation trial of a QVLP vaccine that was both well- QIVs and commercial TIVs [8,9,39,40]. It was also reassuring that we did not see either worsening or induction of allergic symptoms following QVLP exposure and there was no evidence of a potentially immunopathologic IgE response to plant-origin carbohydrate motifs present on the QVLP vaccine.…”

Section: Discussionmentioning

confidence: 83%

A plant-derived quadrivalent virus like particle influenza vaccine induces cross-reactive antibody and T cell response in healthy adults

Pillet

Aubin

Trépanier

et al. 2016

Clinical Immunology

125

101

View full text Add to dashboard Cite

Recent issues regarding efficacy of influenza vaccines have re-emphasized the need of new approaches to face this major public health issue. In a phase 1-2 clinical trial, healthy adults received one intramuscular dose of a seasonal influenza plant-based quadrivalent virus-like particle (QVLP) vaccine or placebo. The hemagglutination inhibition (HI) titers met all the European licensure criteria for the type A influenza strains at the 3μg/strain dose and for all four strains at the higher dosages 21days after immunization. High HI titers were maintained for most of the strains 6months after vaccination. QVLP vaccine induced a substantial and sustained increase of hemagglutinin-specific polyfunctional CD4 T cells, mainly transitional memory and TEMRA effector IFN-γ(+) CD4 T cells. A T cells cross-reactive response was also observed against A/Hong-Kong/1/1968 H3N2 and B/Massachusetts/2/2012. Plant-based QVLP offers an attractive alternative manufacturing method for producing effective and HA-strain matching seasonal influenza vaccines.

show abstract

Section: Discussionmentioning

confidence: 83%

A plant-derived quadrivalent virus like particle influenza vaccine induces cross-reactive antibody and T cell response in healthy adults

Pillet

Aubin

Trépanier

et al. 2016

Clinical Immunology

125

101

View full text Add to dashboard Cite

show abstract

“…Among adults the most common safety complaints were injection-site pain and systemic reactions, such as myalgia, headaches, and fatigue (123,125,127,129,130,309). The first postlicensure safety assessment of VAERS reports covering the 2013-14 and 2014-15 seasons noted a safety profile similar to that of IIV3.…”

Section: Adultsmentioning

confidence: 99%

“…A review of VAERS reports covering the 2011-12 and 2012-13 seasons, the first two seasons that the intradermal IIV3 was available, revealed no new safety concerns (312). A randomized study comparing safety of the newer IIV4 with that of IIV3 revealed a similar adverse event profile (130).…”

Section: Adultsmentioning

confidence: 99%

Prevention and Control of Seasonal Influenza with Vaccines

Grohskopf

Sokolow²,

Broder³

et al. 2016

MMWR Recomm. Rep.

383

279

View full text Add to dashboard Cite

“…Fluzone Intradermal Quadrivalent : This intradermal vaccine is licensed for use in adults aged 18–64 y and was evaluated in 3360 participants in one study in the US 37 . Non-inferiority was demonstrated between the intradermal F-IIV4 and intradermal IIV3 in terms of HI GMTs and SCRs to common strains, and superiority of the immune response to the added influenza type B lineage compared with 2 intradermal IIV3 formulations was also demonstrated.…”

Section: Clinical Evaluation and Characteristics Of Currently Licensementioning

confidence: 99%

A review of the value of quadrivalent influenza vaccines and their potential contribution to influenza control

Ray

Santos²,

Buck

et al. 2017

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

The contribution of influenza B to the seasonal influenza burden varies from year-to-year. Although 2 antigenically distinct influenza B virus lineages have co-circulated since 2001, trivalent influenza vaccines (TIVs) contain antigens from only one influenza B virus. B-mismatch or co-circulation of both B lineages results in increased morbidity and mortality attributable to the B lineage absent from the vaccine. Quadrivalent vaccines (QIVs) contain both influenza B lineages. We reviewed currently licensed QIVs and their value by focusing on the preventable disease burden. Modeling studies support that QIVs are expected to prevent more influenza cases, hospitalisations and deaths than TIVs, although estimates of the case numbers prevented vary according to local specificities. The value of QIVs is demonstrated by their capacity to broaden the immune response and reduce the likelihood of a B-mismatched season. Some health authorities have preferentially recommended QIVs over TIVs in their influenza prevention programmes.

show abstract

Safety and immunogenicity of a quadrivalent intradermal influenza vaccine in adults

Cited by 33 publications

References 17 publications

A plant-derived quadrivalent virus like particle influenza vaccine induces cross-reactive antibody and T cell response in healthy adults

A plant-derived quadrivalent virus like particle influenza vaccine induces cross-reactive antibody and T cell response in healthy adults

Prevention and Control of Seasonal Influenza with Vaccines

A review of the value of quadrivalent influenza vaccines and their potential contribution to influenza control

Contact Info

Product

Resources

About